Evidence map›Paper›PMID 20729559›Full record

ArticleCirculation. Cardiovascular genetics2010

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Marguerite R Irvin, Edmond K Kabagambe, Hemant K Tiwari, Laurence D Parnell, Robert J Straka, Michael Tsai, Jose M Ordovas, Donna K Arnett

Open access · bronzeAbstract read
In one paragraph

Article in Circulation. Cardiovascular genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Impact of theNutrients · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Marguerite R IrvinDepartment of Epidemiology, University of Alabama at Birmingham, USA. irvinr@uab.edu
Edmond K Kabagambe
Hemant K Tiwari
Laurence D Parnell
Robert J Straka
Michael Tsai
Jose M Ordovas
Donna K Arnett
University of Minnesota · USUniversity of Alabama at Birmingham · US

Funding

Genetic and Environmental Determinants of TriglyceridesU01HL072524 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ARNETT, DONNA K · 2002 to 2008
$11.9M
UAB Pre and Post-Doctoral Training Program in BiostatisticsT32NS054584 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUTTER, GARY R · 2007 to 2011
$765k
NHLBI NIH HHS U01 HL072524NHLBI NIH HHS U01HL072524-04NINDS NIH HHS T32 NS054584NINDS NIH HHS T32NS054584
6 · The paper itself

Abstract

backgroundAlthough much is known about the effect of Apolipoprotein E (APOE) alleles on fasting lipid concentrations, less is known about the effect of APOE alleles on postprandial triglyceridemia or the triglyceride response to fenofibrate. METHODS AND

resultsWe evaluated the effects of the APOE locus on fasting and postprandial triglyceride concentrations as part of the Genetics of Lipid Lowering and Diet Network (GOLDN) study. Participants were evaluated after a high-fat meal challenge before (n=1072) and after 3 weeks of daily treatment with 160 mg of fenofibrate (n=738). Mixed models adjusted for sex, age, waist circumference, and family relationship were used to examine the association of the ε4 carrier and ε2 carrier status versus ε3 homozygotes with fasting triglycerides and the area under the curve (AUC) for triglycerides during the high-fat meal challenge. Compared with the ε3/ε3 genotype, ε2 carriers had on average higher fasting triglyceride concentrations (130.5 mg/dL versus 109.3 mg/dL, P<0.001). After fenofibrate treatment, the APOE genotype differences persisted in the fasting state (ε2 carriers: 85.1 mg/dL versus ε3/ε3: 75.9 mg/dL, P<0.05). Carriers of the ε4 allele had significantly higher fasting triglyceride concentrations only prefenofibrate (120.9 mg/dL versus 109.3 mg/dL, P=0.008). APOE alleles did not have an effect on response to fenofibrate. Postprandial triglycerides were significantly higher for ε2 carriers versus ε3 homozygotes (but not ε4 carriers) both before and after fenofibrate treatment (P=0.01 and P=0.005, respectively).

conclusionsAPOE polymorphisms are important determinants of triglyceride concentrations, especially in the fasting state.

Indexed as

Polymorphism, GeneticAdultApolipoproteins EDietary FatsFastingFemaleFenofibrateGenotypeHumansHyperlipidemiasHypolipidemic AgentsMiddle AgedPostprandial PeriodTriglyceridesApolipoproteins EDietary FatsFenofibrateHypolipidemic AgentsTriglycerides

Identifiers

PMID20729559
PMCPMC3119521
OpenAlexW2101201102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.